Biotech · Private company
SkinJect, Inc.
Track this companyFree. Adds SkinJect, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- D-MNA 100µgPhase 2 · Nodular Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- D-MNA 200µgPhase 2 · Nodular Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Doxorubicin-containing MNAPhase 2 · Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Microneedle Array AlonePhase 2 · Nodular Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- 100 µg doxorubicin-containing MNAPhase 1 · Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- 200 µg doxorubicin-containing MNAPhase 1 · Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- 25 µg doxorubicin-containing MNAPhase 1 · Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- 50 µg doxorubicin-containing MNAPhase 1 · Basal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.PHASE2 · COMPLETED · started Sep 3, 2024ClinicalTrials.gov NCT06608238 · fetched Nov 12, 2026
- Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 24, 2021ClinicalTrials.gov NCT04928222 · fetched Nov 12, 2026
- Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)PHASE1 · TERMINATED · started Jun 10, 2020ClinicalTrials.gov NCT03646188 · fetched Nov 12, 2026